Equities

Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)9.35
  • Today's Change0.95 / 11.31%
  • Shares traded15.05m
  • 1 Year change+23.68%
  • Beta0.6476
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

  • Revenue in USD (TTM)0.00
  • Net income in USD-5.88m
  • Incorporated2013
  • Employees3.00
  • Location
    Galmed Pharmaceuticals Ltd16 Tiomkin StreetTEL AVIV-YAFO 6578317IsraelISR
  • Phone+972 36938448
  • Fax+972 36938447
  • Websitehttps://www.galmedpharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Weed Inc0.0057.30k5.31m2.0084.31706.0861.40--0.00050.00050.000.000060.00----0.006.00-385.93---822.37-----------46.080.944------97.93---59.13--
Burzynski Research Institute Inc0.00-1.42m5.40m2.00---------0.0108-0.01080.00-0.0010.00-------153,444.30-15,304.89-------------------------45.74------
Virios Therapeutics Inc0.00-5.30m5.53m4.00--1.76-----0.2603-0.26030.000.1130.00----0.00-119.71-79.80-135.31-89.54------------0.00------56.76------
ELEVAI Labs Inc2.47m-4.75m5.65m18.00--2.00--2.29-0.2698-0.26980.14080.13970.72491.0495.33137,407.20-139.23---285.65--69.25---192.08--0.5439--0.00--123.50---138.94------
Marizyme Inc364.96k-52.51m5.65m11.00------15.49-0.974-0.9740.004-0.07120.01251.3110.0033,178.18-179.49-59.02-742.64-64.4770.1770.38-14,389.19-9,435.920.038-0.69891.92--176.5999.98-71.22------
Galmed Pharmaceuticals Ltd0.00-5.88m6.02m3.00--0.4203-----24.68-24.680.0022.250.00----0.00-44.20-45.06-52.67-50.79------------0.00------61.31------
Transcode Therapeutics Inc0.00-17.91m6.06m10.00--1.93-----75.48-75.480.000.1820.00----0.00-334.48-133.14-973.00-181.26-----------90.110.00-------5.59------
CERo Therapeutics Holdings Inc0.00-2.54m6.11m8.00---------0.3796-0.37960.00-0.92260.00----0.00-9.96---33.80-----------------------279.82------
Xenetic Biosciences Inc2.52m-4.70m6.12m4.00--0.8219--2.43-3.05-3.051.644.830.2314----630,087.50-43.12-48.91-48.61-52.82-----186.33-682.42----0.00--48.80--36.90------
Alzamend Neuro Inc0.00-7.39m6.57m4.00---------10.69-10.690.00-1.410.00----0.00-344.10-177.86---257.81-----------363.62--------33.14------
Cardio Diagnostics Holdings Inc39.14k-8.77m6.70m7.00--2.12--171.28-0.4899-0.48990.00210.13190.0073--9.135,591.43-163.16---268.73-------22,414.13-----9.320.0295--1,696.84---79.72------
Adial Pharmaceuticals Inc0.00-12.19m6.72m4.00--1.05-----5.26-5.300.000.99610.00----0.00-279.27-182.35-320.96-235.45-----------14.250.00------35.14------
Moleculin Biotech Inc0.00-25.17m6.74m18.00--0.3428-----11.62-11.620.006.910.00----0.00-69.24-46.84-83.35-51.49------------0.00-------2.56---21.54--
Eterna Therapeutics Inc162.00k-23.94m6.93m8.00------42.75-4.42-4.420.0299-1.580.0035--0.267320,250.00-51.20-169.05-62.39-223.00-111.11---14,765.43-682.61---10.1210.22-----68.8911.84---58.86--
Data as of Sep 20 2024. Currency figures normalised to Galmed Pharmaceuticals Ltd's reporting currency: US Dollar USD

Institutional shareholders

5.12%Per cent of shares held by top holders
HolderShares% Held
Walleye Capital LLCas of 30 Jun 202424.22k3.75%
Heights Capital Management, Inc.as of 30 Jun 20243.94k0.61%
Morgan Stanley & Co. LLCas of 30 Jun 20242.92k0.45%
G1 Execution Services LLCas of 30 Jun 2024969.000.15%
Two Sigma Securities LLCas of 30 Jun 2024861.000.13%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024102.000.02%
UBS Securities LLCas of 30 Jun 202423.000.00%
TSFG LLCas of 30 Jun 202417.000.00%
Wells Fargo Clearing Services LLCas of 30 Jun 202417.000.00%
Desjardins Securities, Inc.as of 30 Jun 202414.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.